FDA Grants Orphan Drug Designation for BE-101, a Novel Engineered B Cell Medicine, for the Treatment of Hemophilia B June 4, 2024
Be Biopharma Announces New Preclinical Data for Novel B Cell Medicine for the Potential Treatment of Hypophosphatasia May 13, 2024
Be Biopharma to Present at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting April 24, 2024
Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization January 5, 2024
